Preclinical studies involving 89 Zr often report significant bone accumulation, which is associated 24 with dissociation of the radiometal from the tracer. However, experiments determining the 25 uptake of unbound 89 Zr in disease models are not performed as routine controls. The purpose 26 of the present study was to investigate the impact of free or weakly bound 89 Zr on PET 27 quantifications in disease models, in order to determine if such control experiments are 28 warranted. Methods: Chemical studies were carried out to find a 89 Zr compound that would 29 solubilize the 89 Zr as a weak chelate, thus mimicking free or weakly bound 89 Zr released in 30 circulation. 89 Zr oxalate had the desired characteristics, and was injected into mice bearing 31 FaDu and HT29 solid tumor xenografts, and mice infected in the lungs with the mold Aspergillus 32 fumigatus, as well as in healthy controls (naïve). PET/CT and PET/MR imaging followed to 33 quantify the distribution of the radionuclide in the disease models. Results: 89 Zr oxalate was 34 found to have a plasma half-life of 5.1 ± 2.3 h, accumulating mainly in the bones of all animals. 35 Both tumor types accumulated 89 Zr on the order of 2-4% ID/cm 3 , which is comparable to EPR-36 mediated accumulation of certain species. In the aspergillosis model, the concentration of 89 Zr 37 in lung tissue of the naïve animals was 6.0 ± 1.1 %ID/g. This was significantly different from that 38 of the animals with advanced disease, showing 11.6% ± 1.8 %ID/g. Conclusions: Given the high 39 levels of 89 Zr accumulation in the disease sites in the present study, we recommend control 40 experiments mapping the biodistribution of free 89 Zr in any preclinical study employing 89 Zr 41 where bone uptake is observed. Aqueous 89 Zr oxalate appears to be a suitable compound for 42 such studies. This is especially relevant in studies where the tracer accumulation is based upon 43 passive targeting, such as EPR. 44 
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56
The biodistribution of free, or weakly chelated, 89 Zr was investigated in healthy mice by Abou et 57 al. using the chloride, oxalate, phosphate and citrate salts [9] . All salts were found to exhibit 58 similar biodistribution and cause accumulation of 89 Zr in the bones, except the phosphate, 59 which localized to liver and spleen. This was attributed to poor solubility of the 89 Zr phosphate. 60 Holland et al. also found the activity from the 89 Zr oxalate to show pronounced bone 61 accumulation, but found 89 Zr injected as the chloride to accumulate in the liver [8] . This was 62 also attributed to the chloride being prone to hydrolysis and poor solubility. These studies both 63 indicated that free, soluble 89 Zr 4+ will accumulate in bone. 64 
65
The nonspecific biodistribution of free 89 Zr in clinically relevant disease models has not been 66 investigated. However, given the large number of reports showing increased bone uptake in 67 monoclonal antibody imaging, which indicates the presence of free 89 The aim of this work was to investigate the biodistribution of weakly chelated 89 Zr in relevant 95 murine disease models compared to their healthy controls. We set out to determine whether 1) 96 free 89 Zr exhibits accumulation in FaDu and HT29 tumor xenografts in mice and 2) whether 97 biodistribution, especially in lungs, is significantly different between healthy animals and those 98 with pulmonary aspergillosis. Further, the criteria for the injected 89 Zr to be considered 'free', 99 was that it was stable in solution and able to interact and associate with complexing molecules 100 and other blood stream components. For this reason we also investigated a range of 101 complexing ligands for their ability to restrict hydrolysis of 89 Zr and allow chelation by 102 diethylene triamine pentaacetic acid (DTPA). 129 The following experiments were performed to test the ability of various complexing ligands to 130 restrict hydrolysis of 89 Zr and allow chelation by DTPA. To vials containing dry 89 Zr chloride was 131 added 1.3 mL of either 1) saline, 2) 10 mM oxalic acid in saline at pH ≈ 5.5, 3) 10 mM oxalic acid 132 in saline at pH ≈ 7.0, 4) 10 mM citric acid in saline at pH 5.5, 5) 10 mM citric acid in saline at pH 133 7.0, 6) neat ultrapure water, 7) isotonic sucrose solution at 924 mg/mL, 8) 10 mM sodium 134 acetate at pH 5.5 or 9) 10 mM sodium acetate at pH ≈ 7.0. Each preparation was stirred for 10 135 minutes at 37 o C after which 300 µL was removed for pH measurement. In addition, the 136 radioactivity in the total volume (1.3 mL) as well as in the removed 300 µL was measured. To 137 the remaining 1.00 mL was then added aqueous DTPA (50 µL, 50 mM) that had been adjusted 138 to pH 5.5 or pH 7.0, whichever was closest to the pH of the receiving 89 Zr-mixture. To the saline 139 (chloride), water and sucrose mixtures was added DTPA at pH 5.5. The solutions were then 140 stirred at 37 o C and monitored by radio-TLC with samples removed at t = 0 (before addition of 141 DTPA), t = 10 min, t = 30 min and t = 60 min. Each mixture was prepared and analyzed in 142 triplicate. 145 Based on the stability and exchange experiments described above, an oxalate solution was 146 chosen for in vivo use. This was prepared by adding a solution of 10 mM oxalic acid in isotonic 147 saline (pH adjusted to 6.7 with NaOH) to the dried 89 Zr chloride. In order to confirm that the 148 89 Zr was fully dissolved, a sample of the solution was removed and its activity concentration 149 was compared to the remaining fraction. Osmolality and pH were measured, and HPGE gamma 150 spectroscopy was used to determine the radionuclidic purity. ICP-OES, calibrated against Fe, Zr, 151 Zn, Cu, Ag, and Ni standards in 1% (w/v) HCl, was used to quantify metal impurities. 152 Additionally, 300 µl of the 89 Zr oxalate solution was removed and mixed with aqueous DTPA (15 153 µL, 50mM, pH 7.0). After stirring at 37 o C for 30 min, it was analyzed by radio-TLC along with a 154 sample to which no DTPA had been added. After the completion of these tests, the solution 155 was ready for injection in the animal studies. 158 The studies on tumor-bearing mice were approved by the Danish Animal Welfare Council, 189 The studies on A. fumigatus infected and disease-free control mice ("naïve") were performed The A. fumigatus infected mice were divided into two different groups. The first group (n = 5), 226 termed "nascent disease", received the tracer injection immediately after infection. These 227 animals, along with neutropenic uninfected controls (n = 5), "naïve", mice were imaged with 10 228 min PET scans, followed by MR imaging, performed at 3, 24 and 48 h post-injection of the 229 tracers. In the second group (n = 4), termed "advanced disease", infected mice were injected 230 with 89 Zr oxalate 21 hours after infection. This cohort, along with four naïve control animals, 231 was imaged 3 h after tracer injection, followed immediately by ex vivo biodistribution. Despite the fact that several solutions were able to bring 89 Zr into the aqueous environment, it 255 remained necessary to test whether the 89 Zr was still able to transchelate to DTPA. This would 256 ensure that the 89 Zr was not merely suspended as a colloid, and that the complexes in question 257 could easily transfer the radioactivity to other agents. All complexes were tested for 258 transchelation to DTPA, but only the ones with superior transferability are shown in figure 1B . 259 For the remainder, please refer to supplemental materials. Both oxalate mixtures showed fast 260 and efficient transchelation to DTPA, within 10 minutes. On the other hand, the uptake from 261 the citrate was markedly slower, showing a gradual ascent, reaching about 70-80% after one 262 hour. DTPA chelation from the sucrose was faster than from the citrate, but slower than from 263 the oxalate. 273 The results of the quality control analyses for the injected 89 Zr oxalate solutions were consistent 274 with those observed in the transferability/solubility and transchelation tests described above. 275 The transferability of activity in the 89 Zr oxalate in vivo formulation was 95%, indicating that the 276 89 Zr was properly dissolved. The pH value was in the range of 5.5-6.7, which due to the low 277 buffer capacity of the solution was expected to fluctuate. The osmolality was 310 mOsmol/kg, 278 and was appropriate for injection (serum osmolality: 282 -295 mOsmol/kg). Analysis by ICP- Quantifications of the PET data are given in Table 2 . Both tumor types showed significant 294 uptake of 2-4% ID/cm 3 over the course of the study. As expected, bone uptake was prominent, 295 reaching a maximum at 20 h, followed by a plateau at around 13% ID/cm 3 . The tumor-to- 305 The mice infected with A. fumigatus were divided into two groups. In the nascent disease 306 group, where animals received the tracer injection immediately after they had been infected, 307 and their naïve controls, the PET and biodistribution data were independent of disease status 308 (Figure 4A-D) . Quantification of the PET results revealed enhanced uptake of 89 Zr in the spine 309 ( Figure 4C ) without significant differences between the tested groups. The bone uptake pattern 310 is evident by qualitative observation in the 48 h maximum intensity projection (MIP) images in 311 Figure 4E . The mean tracer uptake in the spine of naïve mice increased from 7.5 ± 0.9 %ID/cm 3 312 at 3 h to 18.6 ± 1.0% ID/cm 3 at 24 h, and in infected animals from 7.5 ± 0.3 % ID/cm 3 at 3 h to 313 16.5 ± 1.6 % ID/cm 3 at 24 h after tracer injection, further reflecting the similarity between 314 infected and naïve animals. Figure 6 ) In addition, the uptake of 89 Zr in the spine 321 of naïve animals was significantly higher (6.5 ± 0.7 %ID/cm 3 ) compared to the infected group 322 (4.8 ± 0.3 %ID/cm 3 ; p = 0.0088, Figure 6 ). No significant differences were seen in liver and 323 muscle tissues (Figure 6) . The ex vivo biodistribution from the advanced disease group confirmed the quantification 327 obtained from the PET imaging ( Table 3) . The data from all animals revealed high 328 concentrations of 89 Zr in the bones, blood, and highly blood-perfused organs such as the heart. 329 The %ID/g values of the blood were 10.5 ± 2.7 (naïve animals) and 8.6 ± 2.8 (advanced disease). 330 The ex vivo biodistribution confirmed the significant differences in the lung (p = 0.002) and 331 spine (p = 0.045) uptake between the infected and naïve animals observed with in vivo PET 332 quantification. The weakness in the current practice is that the derived images quantify the distribution of the 356 radionuclide and not necessarily the intact tracer. In general this is a well-understood 357 phenomenon in PET that can be controlled for by metabolite analysis. However, in 89 Zr imaging 358 the problem is rarely addressed. This is surprising because in a large number of pre-clinical 359 studies involving 89 Zr there is heightened bone accumulation in the animals. Such high skeletal 360 uptake is indicative of 89 Zr that is no longer bound to the molecule of interest, but is free or 361 weakly coordinated. Given that there is an observed separation between radionuclide and the 362 traced molecule, it is important to understand how the free radionuclide is affecting the PET 363 data. reported with less than 100% yield [6, 7] , which means either that Df-chelation sites were in 372 shortage or that the reaction had not run to completion. In such cases surplus 89 Zr will be 373 present in the reaction mixture and it is reasonable to assume that some of it could bind non-374 specifically to certain proteins. Finally, it is possible that free 89 Zr arises from metabolism of the 375 radiolabeled entities. 376 377 Regardless of the mechanism by which 89 Zr is released to the circulation, we sought a tracer 378 that would solubilize and efficiently disperse the 89 Zr while restricting irreversible hydrolysis. 379 We found that a solution of the radioactivity in 10 mM oxalate in isotonic saline with a pH of radioactivity in our studies showed prolonged retention in blood suggests that either the 390 activity is shifted to other endogenous carriers with long circulation, or that the 89 Zr oxalate 391 itself is long-circulating. In both cases, since the oxalate is a weak complex, the long circulatory 392 property of the activity is beneficial to its distribution via the routes that could be expected of 393 89 Zr weakly bound to long-circulating species, such as antibodies or nanoparticles. HNSCC had an average uptake of 19 %ID/kg [33] . From these data, it is apparent that uptake in 446 man versus mouse is not directly scalable, but can depend on the mode of accumulation. 447 Accordingly, we propose that if 89 Zr localizes to tumors by transferrin binding and EPR uptake, 448 the impact on proper assessment of tumor uptake may be greater in humans when imaging 449 antibodies that primarily localize by active targeting. were infected with A. fumigatus and after 21 hours of disease progression, they were injected 587 with 10-12 MBq 89 Zr oxalate. Tissues were excised and measured three hours after the injection.
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Data are %ID/g, expressed as the mean or as lung-to-muscle ratios ± 1 SD. Significantly 589 different organs are shown in bold with * (p < 0.05) or ** (p < 0.01). 
